Korea 2021 Roundup: License Deals, Overseas Sales Key Factors In Earnings
Hanmi, GC Pharma, SK Affiliates Strong Performers
A Scrip roundup of 2021 earnings for major Korean pharma firms shows top performers included Hanmi Pharma, GC Pharma and SK Group affiliates, which were boosted by new license deals, strong overseas sales and high-margin vaccines and other products.
You may also be interested in...
German firm’s antibody-drug conjugates use amanitin payload. Plus deals involving Sanwa Kagaku/Crinetics, Takeda/Code Bio, Taro/Alchemee, Mankind/Dr. Reddy’s and more.
Analysts see Hanmi’s clinical-stage asset as fitting well into Aptose's pipeline and providing potential combination therapy benefits for hematological malignancies.
Deal Snapshot: Pharma places $30m upfront wager on biotech’s allogeneic natural killer cell and chimeric antigen receptor technologies, with hopes for solid tumor cell therapies.